SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 102 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $4,144,000 | +4.0% | 381,919 | -15.3% | 0.38% | -16.4% |
Q3 2020 | $3,986,000 | -25.0% | 450,861 | -9.6% | 0.45% | -25.7% |
Q2 2020 | $5,316,000 | +74.9% | 498,666 | -2.7% | 0.61% | +33.1% |
Q1 2020 | $3,040,000 | +34.6% | 512,570 | +56.8% | 0.46% | +100.0% |
Q4 2019 | $2,259,000 | – | 326,847 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |